Safety and Efficacy of Physician-Supervised Self-Managed C1 Inhibitor Replacement Therapy | Zendy

Louanne M. Tourangeau | Zendy; Anthony J. Castaldo | Zendy; Donna K. Davis | Zendy; James A. Koziol | Zendy; Sandra C. Christiansen | Zendy; Bruce L. Zuraw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Efficacy of Physician-Supervised Self-Managed C1 Inhibitor Replacement Therapy

Author(s) -

Louanne M. Tourangeau,

Anthony J. Castaldo,

Donna K. Davis,

James A. Koziol,

Sandra C. Christiansen,

Bruce L. Zuraw

Publication year - 2011

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000329635

Subject(s) - medicine , hereditary angioedema , c1 inhibitor , adverse effect , observational study , physical therapy , angioedema , immunology

C1 inhibitor (C1INH) has recently been approved in the USA for the treatment of acute attacks in hereditary angioedema (HAE) patients. The literature suggests that treatment with C1INH is most effective when administered early in an attack. Home infusion of C1INH allows for the earliest possible intervention since patients can initiate therapy at the first sign of symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research